Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries

April 12, 2017 updated by: Arteriocyte, Inc.

Phase I, Double-Blind, Randomized, Controlled Study to Demonstrate the Safety of Applying Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™) to Acute Deep Partial Thickness Thermal Injuries

The study will examine the safety of using a concentration of proteins from a patient's own blood, referred to as platelet rich plasma or (PRP) and applying it to a second degree burn wound.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The objective of this trial is to demonstrate the safety of applying autologous PRP gel (Magellan® Bio-Bandage™) to acute deep partial thickness thermal burns in the first days after burn injury.

The Magellan® Bio-Bandage™ Burn Wound Care Kit is intended for the preparation and application of an autologous biological covering to deep partial thickness burn wounds to delay or minimize skin grafting requirements.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85008
        • Arizona Burn Center
    • California
      • Sacramento, California, United States, 95817
        • University of California, Davis Medica Center
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • MedStar Health Research Institute
    • Florida
      • Tampa, Florida, United States, 33606
        • Tampa General Hospital/University of South Florida
    • Nevada
      • Las Vegas, Nevada, United States, 89102
        • University Medical Center Southern Nevada, Lions Regional Burn Center
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Jaycee Burn Center at University of North Carolina
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Lehigh Valley Health Network
    • Tennessee
      • Memphis, Tennessee, United States, 38104
        • Firefighters' Regional Burn Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 86 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed consent will be obtained prior to study participation
  • Male or female age ≥ 18 years of age or ≤ 86 years of age
  • Total burn wound measuring ≤ 25% TBSA
  • Burn wound area to be treated must be a deep partial thickness wound
  • Burn wound area to be treated must be ≤72 cm2 and surrounded by a perimeter of healthy skin
  • Able and willing to comply with the procedures required by the protocol. Subjects may be managed as either inpatient or outpatient.
  • If a female of childbearing potential, the subject must have a negative serum pregnancy test at screening
  • All subjects, male and female, must use acceptable method(s) of birth control for the duration of the study
  • Female subjects must be of non childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one of the following methods of birth control):
  • Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry)
  • A partner who is physically unable to impregnate the subject (e.g., vasectomized)
  • Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to subject's cell concentrate administration
  • Intrauterine device (IUD), or
  • Double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)

Exclusion Criteria:

  • Conductive electrical, friction or chemical burns
  • Burns to the digits, head, genitalia, palms of hands, soles of feet, and face that are the only possible sites for treatment (subjects with burns elsewhere in addition to these sites may be enrolled in the study)
  • Burns that pose a risk to digits or limbs
  • Subjects who have gone into hemorrhagic shock following burn injury
  • Subject was medically treated for insulin-dependent or non-insulin-dependent diabetes mellitus prior to burn injury per subject medical history
  • Venous or arterial vascular disorder directly affecting a designated test area
  • Known immune deficiency disorder, either congenital or acquired
  • Chronically malnourished as determined clinically by the investigator. (Investigators are responsible for determining if subjects are chronically malnourished during the screening process. Investigators should take into consideration the following parameters: medical history and physical appearance, the subject's body mass index, and any significant laboratory findings)
  • Severe respiratory problems or concurrent head trauma at hospital admission, including inhalation injury requiring ventilator support
  • Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study
  • Use of COX-1 and/or COX-2 inhibitors within 48 hours prior to treatment. Subjects must refrain from use of NSAIDs for five days after Visit 2.
  • Any other acute or chronic concurrent medical condition(s) that, in the investigator's opinion, are a contraindication to study participation or limit the subject's life expectancy to < 6 months
  • Known or suspected hypersensitivity to Recothrom®
  • Concurrent participation in another clinical trial in which an investigational agent is used. (Subjects must not have been enrolled in another clinical trial within 30 days of enrolling in this trial)
  • Females who are pregnant or nursing or intend to become pregnant during the duration of the study
  • Burn wounds that occur over joints
  • Known allergies to silver, adhesive products or silicone.
  • Subjects with the following abnormal laboratory test levels:
  • Stage 4 or greater chronic kidney disease (eGFR < 30 mL/min
  • Hemoglobin < 10 g/dl
  • Thrombocytopenia < 100,000 platelets/µl.
  • Serum albumin level < 2.5 g/dl or > 30 g/dl at time of screening
  • Liver function*:
  • AST- Males and Females, >2.5 ULN
  • ALT- Males and Females, >2.5 ULN
  • Alkaline Phosphatase- Males and Females: >2.0 ULN
  • Total bilirubin- Males and Females >2.0 ULN

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Platelet Rich Plasma - Bio-Bandage™
Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Device: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
Other Names:
  • The Magellan® System
Sham Comparator: Saline Spray, Standard of Care
Device: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
Other Names:
  • The Magellan® System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety as measured by Adverse Events
Time Frame: Days 1 -365
The primary objective of this trial is to demonstrate the safety of applying autologous PRP gel to acute deep partial thickness thermal burns in the first days after burn injury. The primary endpoint of this study will be safety. Incidence of Adverse Events and/or Serious Adverse Events will be documented, along with time to wound closure.
Days 1 -365

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Delay or minimization of skin grafting requirements following burn injury
Time Frame: Change will be assessed up to 35 Days
This outcome will be evaluated by time to graft (days), need for graft (yes or no), and incidence of graft occurrence ( percentage of subjects in control group versus treatment group requiring a skin graft).
Change will be assessed up to 35 Days
Improved wound healing trajectory as compared to standard of care
Time Frame: Change will be assessed up to 365 Days
Wound healing will be assessed by calculating wound size measurements and percentage of change over time utilizing digital photography and planimetry software.
Change will be assessed up to 365 Days
Increased rate of wound closure as compared to standard of care
Time Frame: Change will be assessed up to 365 Days
The percentage of treated subjects versus standard of care only subjects with complete wound closure at 28 and 42 days post-burn injury. Wound closure will be defined as skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive visits.
Change will be assessed up to 365 Days
Reduced scarring, pain and pruritus
Time Frame: Change will be assessed up to 365 Days
This outcome will compare treated subjects to standard of care only subjects by analyzing photo images and scar scale analysis (principal investigator and blinded rater assessments), and based on subject reported pain and pruritus.
Change will be assessed up to 365 Days
Improved Skin-Healing Quality
Time Frame: Change will be assessed up to 365 Days
Histological analysis of 2mm skin biopsies taken at Baseline (Day 1) and 90 days post-treatment will be analyzed and compared. Biopsies will be taken only from subject for whom a skin graft was not required, and from both treated subjects and standard of care only subjects.
Change will be assessed up to 365 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Arteriocyte, Inc.

Collaborators

Department of Health and Human Services

Investigators

  • Study Director: Brian Barnes, PhD, Arteriocyte, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2014

Primary Completion (Anticipated)

January 1, 2018

Study Completion (Anticipated)

May 1, 2018

Study Registration Dates

First Submitted

May 23, 2014

First Submitted That Met QC Criteria

June 19, 2014

First Posted (Estimate)

June 23, 2014

Study Record Updates

Last Update Posted (Actual)

April 13, 2017

Last Update Submitted That Met QC Criteria

April 12, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • ART 13-005
  • IDE 15921 (Other Identifier: Center for Biologics Evaluation and Research)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Deep Partial Thickness Thermal Burns

Clinical Trials on Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe